Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Bladder Cancer |
Free Subscription
2 Actas Urol Esp (Engl Ed) |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Bladder Cancer is free of charge.
The association between the human papillomavirus (HPV) and the diagnosis of
bladder cancer: systematic review and meta-analysis.
Actas Urol Esp (Engl Ed). 2024 May 9:S2173-5786(24)00062.
PubMed
Abstract available
Use of Bladder Epicheck(R) in the follow-up of high-risk non-muscle-invasive
Bladder cancer: A systematic literature review.
Actas Urol Esp (Engl Ed). 2024 May 10:S2173-5786(24)00064.
PubMed
Abstract available
The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.
Am J Clin Exp Urol. 2024;12:88-99.
PubMed
Abstract available
Elevated expression of SRRM3 in bladder cancer predicts poor prognosis and is
associated with immune infiltration.
Asian J Surg. 2024 May 9:S1015-9584(24)00869.
PubMed
Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By
Tissue-Specific Suppression of SLAMF6 Signaling.
bioRxiv [Preprint]. 2024 May 3:2024.04.30.591366. doi: 10.1101/2024.04.30.591366
PubMed
Abstract available
Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.
BJUI Compass. 2024;5:497-501.
PubMed
Abstract available
NPEPPS Is a Druggable Driver of Platinum Resistance.
Cancer Res. 2024;84:1699-1718.
PubMed
Abstract available
Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables
precision monitoring of urothelial cancer.
Cancer Sci. 2024;115:1602-1610.
PubMed
Abstract available
Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification
Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guerin
Therapy in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1684.
PubMed
Abstract available
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Clin Cancer Res. 2024;30:2181-2192.
PubMed
Abstract available
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for
Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res. 2024;30:2011-2016.
PubMed
Abstract available
Advances in preclinical approaches for intravesical therapy of bladder cancer.
Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
PubMed
Abstract available
Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin
Chemosensitivity in Bladder Cancer Cells.
Curr Pharm Biotechnol. 2024 May 16. doi: 10.2174/0113892010305651240514100129.
PubMed
Abstract available
Prognostic significance and immune landscape of a cell cycle progression-related
risk model in bladder cancer.
Discov Oncol. 2024;15:160.
PubMed
Abstract available
Impact of tumour stroma-immune interactions on survival prognosis and response to
neoadjuvant chemotherapy in bladder cancer.
EBioMedicine. 2024;104:105152.
PubMed
Abstract available
Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of
Bladder Cancer.
Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
PubMed
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Eur Urol. 2024;85:591-592.
PubMed
Health-related Quality of Life in Patients with Previously Treated Advanced
Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus
Chemotherapy.
Eur Urol. 2024;85:574-585.
PubMed
Abstract available
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab
the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Eur Urol Oncol. 2024;7:313-315.
PubMed
Abstract available
On-treatment Modified Glasgow Prognostic Score Provides Predictive Information
Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on
Immunotherapy.
Eur Urol Oncol. 2024;7:328-331.
PubMed
Abstract available
Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus
Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective,
Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In
press. https://doi.org/1
Eur Urol Oncol. 2024;7:636.
PubMed
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in
Preclinical Bladder Cancer Models.
Eur Urol Oncol. 2024 May 15:S2588-9311(24)00115.
PubMed
Abstract available
Retraction: Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC (2014)
Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer
cells. FEBS Letters 588, 4654-4664.
https://doi.org/10.1016/j.febslet.2014.10.037.
FEBS Lett. 2024 May 15. doi: 10.1002/1873-3468.14892.
PubMed
Abstract available
Knockdown of iPLA(2)gamma enhances cisplatin-induced apoptosis by increasing
ROS-dependent peroxidation of mitochondrial phospholipids in bladder cancer
cells.
Free Radic Biol Med. 2024;220:301-311.
PubMed
Abstract available
The clinical effect of gratitude extension-construction theory nursing program on
bladder cancer patients with fear of cancer recurrence.
Front Oncol. 2024;14:1364702.
PubMed
Abstract available
Our Experience of OSAKA Regimen (Bladder Preservation) in Patients with Advanced
Bladder Cancer.
Indian J Surg Oncol. 2024;15:264-267.
PubMed
Abstract available
Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for
Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical
Administration.
Int J Mol Sci. 2024;25:4945.
PubMed
Abstract available
Exposure of Bladder Cancer Cells to Blue Light (lambda = 453 nm) in the Presence of
Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
Int J Mol Sci. 2024;25:4868.
PubMed
Abstract available
Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor
Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary
Urothelial Carcinoma after BCG Immunotherapy.
Int J Mol Sci. 2024;25:4776.
PubMed
Abstract available
The clinical significance of PD-1 expression in patients with bladder cancer
without lymph node metastasis: a comparative study with drained lymph nodes and
tumor tissues.
Int J Neurosci. 2024 May 14:1-17. doi: 10.1080/00207454.2024.2356152.
PubMed
Abstract available
Comment on 'Robot-assisted radical cystectomy with intracorporeal urinary
diversion: an updated systematic review and meta-analysis of its differential
effect on effectiveness and safety'.
Int J Surg. 2024;110:3114-3115.
PubMed
Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+
T-cell - fibroblast subtype predicting prognosis and immune therapeutic response
of bladder cancer, based on machine-learning bioinformatics retrospective study.
Int J Surg. 2024 May 17. doi: 10.1097/JS9.0000000000001516.
PubMed
Abstract available
Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who
undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective
cohort study of 115 advanced bladder cancer patients with pathological lymph node
classification
Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
PubMed
Editorial comment for "Surgeon-administered regional nerve blocks during radical
cystectomy: a feasibility study".
Int Urol Nephrol. 2024;56:1937-1938.
PubMed
Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory
Roundtable and Literature Review.
J Clin Med. 2024;13:2637.
PubMed
Abstract available
Investigation of Knowledge, Attitudes, and Healthy Lifestyle Behaviors on Bladder
Cancer in Turkey.
J Med Invest. 2024;71.
PubMed
Abstract available
Bladder Cancer, Version 3.2024.
J Natl Compr Canc Netw. 2024;22:216-225.
PubMed
Abstract available
Screening for urothelial carcinoma cells in urine based on digital holographic
flow cytometry through machine learning and deep learning methods.
Lab Chip. 2024;24:2736-2746.
PubMed
Abstract available
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer
without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm,
multicentre, phase 2 trial.
Lancet Oncol. 2024 May 10:S1470-2045(24)00178.
PubMed
Abstract available
Can the use of antithrombotic drugs be a predictive factor in the early diagnosis
of bladder cancer?: A single-center analysis.
Medicine (Baltimore). 2024;103:e38228.
PubMed
Abstract available
Causal effects of BMI, waist circumference, and body fat percentage on the risk
of bladder cancer: A Mendelian randomization study.
Medicine (Baltimore). 2024;103:e38231.
PubMed
Abstract available
Dietary fibre supplementation enhances radiotherapy tumour control and alleviates
intestinal radiation toxicity.
Microbiome. 2024;12:89.
PubMed
Abstract available
The impact of purified protein derivative prior to intravesical bacillus
Calmette-Guerin for the treatment of patients with non-muscle invasive bladder
cancer.
Minerva Urol Nephrol. 2024 May 17. doi: 10.23736/S2724-6051.23.05515.
PubMed
Abstract available
Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck(R) as a
diagnostic tool in upper urinary tract tumor.
Minerva Urol Nephrol. 2024;76:195-202.
PubMed
Abstract available
Nucleoporin 93 Regulates Cancer Cell Growth and Stemness in Bladder Cancer via
Wnt/beta-Catenin Signaling.
Mol Biotechnol. 2024 May 14. doi: 10.1007/s12033-024-01184.
PubMed
Abstract available
[Retracted] MicroRNA?539 inhibits the proliferation and invasion of bladder
cancer cells by regulating IGF?1R.
Mol Med Rep. 2024;30:116.
PubMed
Abstract available
Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular
vesicles are involved in tumor-associated macrophage-mediated cisplatin
resistance in bladder cancer.
Mol Oncol. 2024 May 15. doi: 10.1002/1878-0261.13659.
PubMed
Abstract available
Risk of prostate cancer death in men diagnosed with prostate cancer at
cystoprostat-ectomy. A nationwide population-based study.
Scand J Urol. 2024;59:98-103.
PubMed
Abstract available
Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
Ther Adv Med Oncol. 2024;16:17588359241249068.
PubMed
Abstract available
Music from noise-canceling headphones is beneficial against anxiety in male
bladder cancer patients undergoing follow-up cystoscopy: A prospective randomized
trial.
Urol Int. 2024 May 10. doi: 10.1159/000539312.
PubMed
Abstract available
Unveiling the Etiology of Urological Tumors: A Systematic Review of Mendelian
Randomization Applications in Renal Cell Carcinoma, Bladder Cancer, and Prostate
Cancer.
Urol J. 2024 May 11. doi: 10.22037/uj.v21i.7970.
PubMed
Abstract available
Pathology focused review of morphologic subtypes and molecular variants of
urothelial carcinoma with an emphasis on clinical/treatment relevance.
Urol Oncol. 2024;42:193-202.
PubMed
Abstract available
Estimation of the incidence of urachal cancer: A systematic review and
meta-analysis of registry-based studies.
Urol Oncol. 2024;42:221.
PubMed
Abstract available
Effects of androgen suppression therapy on the incidence and prognosis of bladder
cancer: An updated systematic review and meta-analysis.
Urol Oncol. 2024 May 9:S1078-1439(24)00431-9. doi: 10.1016/j.urolonc.2024.
PubMed
Abstract available
BCG and bladder cancer. Forty-eight years after Morales report.
Urologia. 2024 May 17:3915603241252909. doi: 10.1177/03915603241252909.
PubMed
Abstract available
Induction and maintenance of sequential intravesical gemcitabine/docetaxel for
intermediate and high-risk non-muscle invasive bladder cancer with different
dosage protocols.
World J Urol. 2024;42:315.
PubMed
Abstract available
Zhong Nan Da Xue Xue Bao Yi Xue Ban
Molecular mechanisms of ferroptosis and its effects on bladder cancer.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49:286-295.
PubMed
Abstract available
Thank you for your interest in scientific medicine.